CY1116143T1 - Παραγωγα χρωμενονης με αντικαρκινικη δραση - Google Patents

Παραγωγα χρωμενονης με αντικαρκινικη δραση

Info

Publication number
CY1116143T1
CY1116143T1 CY20151100157T CY151100157T CY1116143T1 CY 1116143 T1 CY1116143 T1 CY 1116143T1 CY 20151100157 T CY20151100157 T CY 20151100157T CY 151100157 T CY151100157 T CY 151100157T CY 1116143 T1 CY1116143 T1 CY 1116143T1
Authority
CY
Cyprus
Prior art keywords
chromenone derivatives
cancer action
chromenone
derivatives
cancer
Prior art date
Application number
CY20151100157T
Other languages
English (en)
Inventor
Bernard Christophe Barlaam
Sebastien Louis Degorce
Der Brempt Christine Marie Paul Lambert-Van
Remy Robert Morgentin
Patrick Ple
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CY1116143T1 publication Critical patent/CY1116143T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η εφεύρεση αφορά παράγωγα χρωμενόνης του Τύπου (I) ή φαρμακευτικά αποδεκτά άλατα αυτών, όπου καθένα από τα R1, R2, R3, R4, R5, R6, R7, n και R8 έχει την έννοια που ορίζεται στο παρόν στην περιγραφή, διαδικασίες για την παρασκευή τους, φαρμακευτικές συνθέσεις που τα περιέχουν και χρήση τους στην παρασκευή φαρμάκων για χρήση στην θεραπεία διαταραχών αναπαραγωγής κυττάρων.
CY20151100157T 2009-10-27 2015-02-13 Παραγωγα χρωμενονης με αντικαρκινικη δραση CY1116143T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09306017 2009-10-27
EP10769052.1A EP2493870B1 (en) 2009-10-27 2010-10-25 Chromenone derivatives with anti -tumour activity

Publications (1)

Publication Number Publication Date
CY1116143T1 true CY1116143T1 (el) 2017-02-08

Family

ID=43085922

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100157T CY1116143T1 (el) 2009-10-27 2015-02-13 Παραγωγα χρωμενονης με αντικαρκινικη δραση

Country Status (41)

Country Link
US (5) US8399460B2 (el)
EP (1) EP2493870B1 (el)
JP (2) JP5657010B2 (el)
KR (1) KR101738195B1 (el)
CN (2) CN104447657B (el)
AR (1) AR078786A1 (el)
AU (1) AU2010311107B9 (el)
BR (1) BR112012010124B8 (el)
CA (1) CA2776994C (el)
CL (1) CL2012001056A1 (el)
CO (1) CO6541528A2 (el)
CR (1) CR20120217A (el)
CU (1) CU20120069A7 (el)
CY (1) CY1116143T1 (el)
DK (1) DK2493870T3 (el)
DO (1) DOP2012000124A (el)
EA (1) EA020523B9 (el)
EC (1) ECSP12011838A (el)
ES (1) ES2530943T3 (el)
GT (1) GT201200126A (el)
HK (2) HK1174027A1 (el)
HN (1) HN2012000889A (el)
HR (1) HRP20150146T1 (el)
IL (1) IL219191A0 (el)
IN (1) IN2012DN03328A (el)
ME (1) ME02050B (el)
MX (1) MX2012005027A (el)
MY (1) MY179833A (el)
NI (1) NI201200081A (el)
NZ (1) NZ599457A (el)
PE (1) PE20130149A1 (el)
PL (1) PL2493870T3 (el)
PT (1) PT2493870E (el)
RS (1) RS53813B1 (el)
SA (1) SA110310808B1 (el)
SI (1) SI2493870T1 (el)
SM (1) SMT201500036B (el)
TW (1) TWI483939B (el)
UA (1) UA107474C2 (el)
UY (1) UY32978A (el)
WO (1) WO2011051704A1 (el)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2307400B1 (en) 2008-05-30 2014-04-23 Amgen, Inc Inhibitors of pi3 kinase
US8399460B2 (en) * 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
US8530470B2 (en) * 2011-04-13 2013-09-10 Astrazeneca Ab Chromenone derivatives
BR112015017331B1 (pt) 2013-01-23 2022-01-11 Astrazeneca Ab Compostos de formula i, forma cristalina, uso dos compostos, combinação e composição
RU2666999C2 (ru) * 2013-03-04 2018-09-13 Астразенека Аб Комбинированное лечение
EP3154958B1 (en) 2014-06-13 2020-10-07 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
BR112016028642A2 (pt) 2014-06-13 2017-08-22 Gilead Sciences Inc composto, composição farmacêutica, método de tratamento de uma doença ou condição, método de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase, método de inibição de reações imunes ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, e, uso de um composto, de um sal, de um isômero ou de uma mistura farmaceuticamente aceitável do mesmo.
KR20170015508A (ko) 2014-06-13 2017-02-08 길리애드 사이언시즈, 인코포레이티드 포스파티딜이노시톨 3-키나제 억제제로서의 퀴나졸리논 유도체
EP3154969B1 (en) 2014-06-13 2019-10-09 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
SG11201610088XA (en) 2014-06-13 2016-12-29 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors
CN104803921A (zh) * 2015-03-14 2015-07-29 长沙深橙生物科技有限公司 一种苯取代嘧啶衍生物的制备方法
CN104744376A (zh) * 2015-03-14 2015-07-01 长沙深橙生物科技有限公司 一种2-异丙基嘧啶衍生物的制备方法
KR101766731B1 (ko) 2015-06-23 2017-08-10 충남대학교산학협력단 강심 활성을 갖는 크로메논 유도체 및 이를 포함하는 심부전의 예방 또는 치료용 약학 조성물
US10526316B2 (en) * 2015-10-09 2020-01-07 Janssen Pharmaceutica Nv Quinoxaline and pyridopyrazine derivatives as PI3Kβ inhibitors
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
WO2018057808A1 (en) 2016-09-23 2018-03-29 Gilead Sciences, Inc. Benzimidazole derivatives and their use as phosphatidylinositol 3-kinase inhibitors
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
AR121719A1 (es) 2020-04-03 2022-06-29 Petra Pharma Corp Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
KR20210141214A (ko) * 2020-05-15 2021-11-23 제이투에이치바이오텍 (주) 3원환 화합물 및 이의 의약 용도
IL304895A (en) * 2021-02-01 2023-10-01 Geode Therapeutics Inc INHIBITORS OF PHOSPHOINOSITIDE 3 KINASE BETA Preparations containing them and their use for treatment
AU2022268900A1 (en) * 2021-05-03 2023-11-16 Petra Pharma Corporation Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease
AU2022269566A1 (en) * 2021-05-03 2023-11-02 Petra Pharma Corporation Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease
TWI829179B (zh) * 2021-05-27 2024-01-11 美商佩特拉製藥公司 用於治療疾病之磷酸肌醇3-激酶(pi3k)異位色烯酮抑制劑
WO2023104111A1 (en) * 2021-12-08 2023-06-15 Nanjing Zenshine Pharmaceuticals Co., Ltd. Fused heterocyclic compounds as pi3kalpha inhibitors
WO2024003241A1 (en) 2022-06-30 2024-01-04 Astrazeneca Ab Treatment for immuno-oncology resistant subjects with an anti pd-l1 antibody an antisense targeted to stat3 and an inhibitor of ctla-4
WO2024081904A1 (en) * 2022-10-14 2024-04-18 Genesis Therapeutics, Inc. Methods for treating cancer

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6027A (en) * 1849-01-09 Rotary blacksmith s twyer
HUT58310A (en) 1988-12-21 1992-02-28 Upjohn Co Anti-atherosclerotic and anti-thrombotic 1-benzopyran-4-one- and 2-amino-1,3-benzoxazin-4-one derivatives, process for producing them and pharmaceutical compositions containing them
DE69127690T2 (de) 1990-06-20 1998-02-12 Pharmacia & Upjohn Company Kal Antiatherosklerotische und antithrombotische 1-benzopyran-4-on- und 2-amino-1,3-benzoxazin-4-on-derivate
DE4318756A1 (de) 1993-06-05 1994-12-08 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
BR9707495A (pt) 1996-02-13 1999-07-27 Zeneca Ltd Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
KR100489174B1 (ko) 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-아닐리노퀴나졸린유도체
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
PL199802B1 (pl) 1999-02-10 2008-10-31 Astrazeneca Ab Pochodne chinazoliny, sposoby ich wytwarzania, ich kompozycje farmaceutyczne i ich zastosowania
EP1257537B1 (en) 2000-01-24 2007-05-30 AstraZeneca AB Therapeutic morpholino-substituted compounds
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
US20050277627A1 (en) 2000-07-07 2005-12-15 Arnould Jean C Colchinol derivatives as vascular damaging agents
KR20030022264A (ko) 2000-07-07 2003-03-15 앤지오젠 파마슈티칼스 리미티드 신생 혈관 형성 억제제인 콜치놀 유도체
JP4646626B2 (ja) * 2002-08-16 2011-03-09 アストラゼネカ アクチボラグ ホスホイノシチド３−キナーゼβの阻害
AR054438A1 (es) * 2005-04-15 2007-06-27 Kudos Pharm Ltd Inhibidores de adn -pk
WO2007045876A1 (en) 2005-10-21 2007-04-26 Merz Pharma Gmbh & Co. Kgaa Chromenones and their use as modulators of metabotropic glutamate receptors
SI2004654T1 (sl) * 2006-04-04 2013-11-29 The Regents Of The University Of California Pirazolopirimidinski derivati za uporabo kot kinazni antagonisti
WO2008064244A2 (en) 2006-11-20 2008-05-29 The Trustees Of Columbia University In The City Of New York Phosphoinositide modulation for the treatment of neurodegenerative diseases
EP2112145A1 (en) 2008-04-24 2009-10-28 AxoGlia Therapeutics S.A. Chromenone derivatives useful for the treatment of neurodegenerative diseases
WO2010134082A1 (en) 2009-05-21 2010-11-25 Proteologics Ltd Chromenone derivatives for treatment of cancer
US8399460B2 (en) * 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives

Also Published As

Publication number Publication date
JP5657010B2 (ja) 2015-01-21
ME02050B (me) 2015-05-20
BR112012010124B1 (pt) 2021-02-17
PT2493870E (pt) 2015-02-18
KR101738195B1 (ko) 2017-05-19
AR078786A1 (es) 2011-11-30
EP2493870A1 (en) 2012-09-05
US20160272607A1 (en) 2016-09-22
CN104447657B (zh) 2016-08-17
HK1174027A1 (en) 2013-05-31
EA020523B9 (ru) 2015-01-30
CL2012001056A1 (es) 2012-10-05
US8399460B2 (en) 2013-03-19
US9718800B2 (en) 2017-08-01
SMT201500036B (it) 2015-05-05
UY32978A (es) 2011-05-31
IN2012DN03328A (el) 2015-10-23
CA2776994A1 (en) 2011-05-05
US8673906B2 (en) 2014-03-18
AU2010311107B2 (en) 2014-03-27
BR112012010124A2 (pt) 2016-06-07
US20110098271A1 (en) 2011-04-28
IL219191A0 (en) 2012-06-28
WO2011051704A1 (en) 2011-05-05
CN102712615B (zh) 2014-12-17
TWI483939B (zh) 2015-05-11
KR20120098724A (ko) 2012-09-05
HRP20150146T1 (hr) 2015-05-22
CN102712615A (zh) 2012-10-03
NZ599457A (en) 2014-04-30
HN2012000889A (es) 2015-08-03
GT201200126A (es) 2014-03-03
EA020523B1 (ru) 2014-11-28
TW201121960A (en) 2011-07-01
US20140194419A1 (en) 2014-07-10
EA201200618A1 (ru) 2012-12-28
DK2493870T3 (en) 2015-02-23
MY179833A (en) 2020-11-17
ECSP12011838A (es) 2012-06-29
EP2493870B1 (en) 2014-12-17
CO6541528A2 (es) 2012-10-16
JP2015078202A (ja) 2015-04-23
PE20130149A1 (es) 2013-03-10
AU2010311107B9 (en) 2014-06-19
JP2013508449A (ja) 2013-03-07
CA2776994C (en) 2017-10-31
US20130158026A1 (en) 2013-06-20
PL2493870T3 (pl) 2015-04-30
DOP2012000124A (es) 2012-07-15
CN104447657A (zh) 2015-03-25
JP5872016B2 (ja) 2016-03-01
US20160060240A1 (en) 2016-03-03
NI201200081A (es) 2012-11-07
HK1206335A1 (zh) 2016-01-08
CU20120069A7 (es) 2012-10-15
ES2530943T3 (es) 2015-03-09
AU2010311107A1 (en) 2012-05-03
UA107474C2 (uk) 2015-01-12
SI2493870T1 (sl) 2015-03-31
CR20120217A (es) 2012-06-28
RS53813B1 (en) 2015-06-30
SA110310808B1 (ar) 2013-11-24
MX2012005027A (es) 2012-09-07
BR112012010124B8 (pt) 2021-05-25
US9029374B2 (en) 2015-05-12

Similar Documents

Publication Publication Date Title
CY1116143T1 (el) Παραγωγα χρωμενονης με αντικαρκινικη δραση
CY1121452T1 (el) Παραγωγα πουρινης για τη θεραπευτικη αντιμετωπιση ιικων λοιμωξεων
CY1118771T1 (el) Μακροκυκλικα παραγωγα για την αγωγη υπερπλαστικων παθησεων
CY1119387T1 (el) Τριαζολοπυραζινες ως αναστολεις brd4 για χρηση στην αντιμετωπιση καρκινου
UY33606A (es) DERIVADOS DE PIRAZINA COMO BLOQUEADORES DE ENaC
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
UY31183A1 (es) Derivados de pirazinona y procesos para su preparación
UA115558C2 (uk) Алкілпіримідинові похідні для лікування вірусних інфекцій та подальших захворювань
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
CR20180232A (es) Macrociclos peptídicos contra acinetobacter baumannii
CU20110208A7 (es) Derivados de la piridina de tieno (2,3-b) como inhibidores virales de la réplica
UA113651C2 (xx) Макроциклічні пурини для лікування вірусних інфекцій
CO6470845A2 (es) Derivados de pirimidina novedosos y su uso en el tratamiento del cancer y enfermedades adicionales
PH12015500713B1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
BR112015019590A2 (pt) derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
EA201590862A1 (ru) Фармацевтические композиции
UY31351A1 (es) (ciclopropilfenil)feniloxamidas, procedimiento para su preparación y su uso como medicamentos
BR112014023384A8 (pt) inibidores de bace espirocíclicos de di-hidro-tiazina e di-hidro-oxazina, e composições e usos dos mesmos.
CY1111442T1 (el) Ενωσεις πιπεριδινης και χρησεις αυτων
MD20160053A2 (ro) Derivaţi ai purinei 2,6-substituite şi utilizarea acestora în tratamentul tulburărilor proliferative
MX2015004362A (es) Derivados de ketamina.
CY1120101T1 (el) Παραγωγο πυριδονης και φαρμακο που το περιεχει
CY1115600T1 (el) Πιπεραζινες ως ανθελονοσιακοι παραγοντες
UY31805A (es) Agonistas m1, composiciones farmacéuticas de los mismos, procesos para su preparacion y sus usos para el tratamiento del dolor